Let's focus on what we can do!

By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

  • Home
  • >
  • Bipolar Disorder
  • >
  • RPS warns of ‘huge extra cost’ to NHS after bipolar drug withdrawn – The Pharmaceutical Journal

RPS warns of ‘huge extra cost’ to NHS after bipolar drug withdrawn – The Pharmaceutical Journal

Wednesday, 9 September, 2020

RPS warns of ‘huge extra cost’ to NHS after bipolar drug withdrawn – The Pharmaceutical Journal

Essential Pharma is planning to discontinue production of first-line bipolar disorder treatment Priadel next year, leaving a range of more expensive alternatives on the market.

Source: DR P. MARAZZI/SCIENCE PHOTO LIBRARY
Essential Pharma, the manufacturer of Priadel, has said the drug is no longer a viable product “due to restrictions on permitted pricing”

 
The Royal Pharmaceutical Society (RPS) has said it is ”deeply concerned” and warned of the “huge extra cost” to the NHS after a manufacturer announced plans to discontinue production of one of its branded lithium carbonate products.

In August 2020, Essential Pharma said it would be discontinuing production of Priadel 200mg and 400mg — used as a first-line treatment for bipolar disorder — in April 2021 “due to restrictions on permitted pricing”, making the product “no longer viable”.

Click here to read full article https://www.pharmaceutical-journal.com/news-and-analysis/news/rps-warns-of-huge-extra-cost-to-nhs-after-bipolar-drug-withdrawn/20208308.article

Categories :
  • Bipolar Disorder
  • Latest Headlines
Socials :

Recent posts